Moreover, ponatinib is being tested in clinical trials to evaluate its activity in FLT3-internal tandem duplication (ITD) acute myelogenous leukemia, head and neck cancers, certain type of lung cancer, gastrointestinal stromal tumours and other malignancies. Here, FLT3 is linked to lung cancer.